Nebenwirkungen · Filsuvez
Filsuvez gel · Abschnitt 4.8 · PDF-Seite 4
HOS-144037 · Präparat HOS-099092
The most frequently observed adverse reactions were wound complication (in 11.6% of EB patients and 2.9% of patients with other partial thickness wounds (PTW)), application site reaction (in 5.8% of EB patients), wound infections (in 4.0% of EB patients), pruritus (in 3.1% of EB patients and 1.3% of patients with other PTW), pain of skin (in 2.5% of patients with other PTW) and hypersensitivity reactions (in 1.3% of EB patients). There were no clinically relevant differences in the reactions reported in EB patients compared to patients with other PTW.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-06T10:42:00Z · SHA-256 ddb77f450cc164cb116440828840b5e97772043c4d186a40a1b0fa34842cfd92 · Passage ea861e09a2886840e786f3ae0bb763d89b72eec885208a52061f5c6565ab9b5c · Zeichen 31–588 im Abschnitt